News & Events
  Keeping you informed

Co-Founder of Clemson University spinoff talks about company’s capabilities in predicting chemotherapy success

Written by  in category 
November 20, 2019

Cancer is the second leading cause of death globally and was responsible for over 9.5 million deaths in 2018, as reported by the American Cancer Society. With over 17 million new cases in the past year, this disease can ravage an apparently healthy person within a matter of months. The effects of treatment methods, such as radiation and chemotherapy, can be an entirely separate, yet equally grueling battle for cancer patients.

KIYATEC, a Clemson University biotech spinoff founded in 2005 by Matthew Gevaert and David Orr, is currently developing innovative techniques that will assist healthcare providers in determining which chemotherapy drugs will be the most effective on individual ovarian cancer patients, using KIYATEC’s Ex Vivo 3D Cell Culture technology (EV3D). 

EV3D, a technology that grew out of research conducted at Clemson University, is a novel method that allows scientists to insert a patient’s cancer cells into a three-dimensional cell culture, an environment that more closely resembles the human body, rather than a traditional, flat petri dish. Using these cell cultures, researchers are able to determine which chemotherapy drugs are the most effective on a person-by-person basis with 89% accuracy rate. 

Based in Greenville, SC, KIYATEC tirelessly works to create a better future for cancer patients. Their research and accomplishments have allowed KIYATEC to make a significant impact on the world of health care. 

To learn more about KIYATEC, click here.

About KIYATEC, Inc.

KIYATEC leverages its proprietary ex vivo 3D cell culture technology platforms to accurately model and predict response to approved and investigational cancer drugs targeting a spectrum of solid tumors. The company’s Drug Development Services business works in partnership with leading biopharmaceutical companies to unlock response dynamics for their investigational drug candidates across the majority of solid tumor types. The company’s Clinical Services business is currently engaged in the validation of clinical assays as well as investigator-initiated studies in ovarian cancer, breast cancer, glioblastoma and rare tumors, in its CLIA-certified laboratory. To learn more about KIYATEC, visit

No Responses

    Leave a Reply

    Your email address will not be published. Required fields are marked *